» Articles » PMID: 19144817

Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus

Overview
Specialty Microbiology
Date 2009 Jan 16
PMID 19144817
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Human papillomavirus (HPV) infection is a necessary cause of cervical cancer and cervical dysplasia. Accurate and sensitive genotyping of multiple oncogenic HPVs is essential for a multitude of both clinical and research uses. We developed a modified general primer (MGP) PCR system with five forward and five reverse consensus primers. The MGP system was compared to the classical HPV general primer system GP5+/6+ using a proficiency panel with HPV plasmid dilutions as well as cervical samples from 592 women with low-grade cytological abnormalities. The reference method (GP5+/6+) had the desirable high sensitivity (five copies/PCR) for five oncogenic HPV types (HPV type 16 [HPV-16], HPV-18, HPV-56, HPV-59, and HPV-66). The MGP system was able to detect all 14 oncogenic HPV types at five copies/PCR. In the clinical samples, the MGP system detected a significantly higher proportion of women with more than two concomitant HPV infections than did the GP5+/6+ system (102/592 women compared to 42/592 women). MGP detected a significantly greater number of infections with HPV-16, -18, -31, -33, -35, -39, -42, -43, -45, -51, -52, -56, -58, and -70 than did GP5+/6+. In summary, the MGP system primers allow a more sensitive amplification of most of the HPV types that are established as oncogenic and had an improved ability to detect multiple concomitant HPV infections.

Citing Articles

Cervical cancer microbiome analysis: comparing HPV 16 and 18 with other HPV types.

Hidjo M, Mukhedkar D, Masimirembwa C, Lei J, Arroyo Muhr L Sci Rep. 2024; 14(1):22014.

PMID: 39317706 PMC: 11422507. DOI: 10.1038/s41598-024-73317-8.


A pilot study of risk-stratified cervical cancer screening.

Wang J, Elfstrom K, Borgfeldt C, Dillner J Open Res Eur. 2023; 1:84.

PMID: 37645164 PMC: 10445943. DOI: 10.12688/openreseurope.13398.2.


Increased prevalence of human papillomavirus in fresh tissue from penile cancers compared to non-malignant penile samples: a case-control study.

Kristiansen S, Bjartling C, Torbrand C, Grelaud D, Lindstrom M, Svensson A BMC Cancer. 2022; 22(1):1227.

PMID: 36443686 PMC: 9703753. DOI: 10.1186/s12885-022-10324-w.


Human papillomavirus genotyping using next generation sequencing (NGS) in cervical lesions: Genotypes by histologic grade and their relative proportion in multiple infections.

Basiletti J, Valls J, Poklepovich T, Fellner M, Rol M, Alonso R PLoS One. 2022; 17(11):e0278117.

PMID: 36417453 PMC: 9683586. DOI: 10.1371/journal.pone.0278117.


Co-testing in cervical screening among 40- to 42-year-old women is unreasonable.

Borgfeldt C, Leksell A, Forslund O Acta Obstet Gynecol Scand. 2022; 101(3):374-378.

PMID: 34988970 PMC: 9564562. DOI: 10.1111/aogs.14311.


References
1.
Cuschieri K, Cubie H . The role of human papillomavirus testing in cervical screening. J Clin Virol. 2005; 32 Suppl 1:S34-42. DOI: 10.1016/j.jcv.2004.11.020. View

2.
Dillner J, Arbyn M, Dillner L . Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2007; 148(2):199-207. PMC: 1868871. DOI: 10.1111/j.1365-2249.2007.03384.x. View

3.
Soderlund-Strand A, Dillner J, Carlson J . High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem. 2007; 54(1):86-92. DOI: 10.1373/clinchem.2007.092627. View

4.
Brink A, Snijders P, Meijer C, Berkhof J, Verheijen R . HPV testing in cervical screening. Best Pract Res Clin Obstet Gynaecol. 2005; 20(2):253-66. DOI: 10.1016/j.bpobgyn.2005.10.009. View

5.
Klug S, Molijn A, Schopp B, Holz B, Iftner A, Quint W . Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol. 2008; 80(7):1264-74. DOI: 10.1002/jmv.21191. View